Navigation Links
Parkinson's Transplant Mystery Solved, Researchers Say
Date:6/30/2010

By Jenifer Goodwin
HealthDay Reporter

WEDNESDAY, June 30 -- Researchers believe they know why Parkinson's disease patients who received fetal cell transplants in the 1990s developed uncontrolled, involuntary movements, and they think they can prevent the troublesome side effect.

The findings could potentially make the transplant trials viable again, they said.

"These findings lend much optimism to new human trials testing the safety and efficiency of fetal or stem cell transplantation in Parkinson's patients," said study author Dr. Marios Politis, a clinical scientist at Imperial College London, whose report is published in the June 30 issue of Science Translational Medicine.

In the early 1990s, scientists were excited about promising results of clinical trials using fetal cell transplants to treat Parkinson's disease.

But the excitement was short-lived. A few years later, trials were halted after patients who received the transplants began to experience dyskinesias, or uncontrolled movements.

The new research attributes the involuntary movements in two patients who received transplants in Britain in 1993 and 1996 to an excess of serotonin cells in the transplanted tissue.

Parkinson's disease is a degenerative disorder in which the brain has a shortage of the neurotransmitter dopamine, leading to muscle rigidity, tremors and gait difficulties, and eventually cognitive trouble.

The hope for fetal cell transplants was that the tissue from midbrains of aborted fetuses could be put into Parkinson's patients' brains, replacing the dopamine-producing cells destroyed by the disease.

But results in human studies were unpredictable and controversial, Politis said. In the 1980s, the U.S. government banned fetal cell research, but lifted the ban in the early 1990s.

While some patients who had the transplants showed remarkable improvement -- the two in the study, for example, needed no medication for Parkinson's -- not everyone improved, Politis said.

And over time, the majority of transplanted patients suffered dyskinesias, leading ethics commissions around the world to end human trials in the 1990s, he said.

In the new study, using brain imaging, Politis and his colleagues found that the dopamine neurons that decay in Parkinson's disease were restored and functioning in the two patients. But they also found abnormal levels of serotonin neurons within the transplanted tissue.

The serotonin neurons were releasing dopamine, which, when coming from the wrong source, caused the jerking movements.

When patients were given a serotonin receptor agonist, a drug that prevented the serotonin neurons from firing, the involuntary movements ceased.

"Both patients responded by a sudden and almost complete resolution of the troublesome abnormal movements, suggesting that the excess serotonergic neurons had in fact been pumping out dopamine, causing the dyskinesias," Politis said.

It's possible that removing serotonin cells during the preparation of transplanted tissue in future trials will prevent side effects from developing, he added.

"We believe the first priority is to make the whole procedure more safe," Politis said. "We need to establish patients won't have anything worse happening to them after the surgery. And this study addresses that."

European and North American researchers plan a new round of human trials with fetal cells in Parkinson's disease in 2012, Politis said.

Dr. Michael S. Okun, national medical director for the National Parkinson Foundation, said the study "offers some potentially important insights into the role of serotonin in off-medication dyskinesias that may be encountered following Parkinson's disease fetal cell grafting."

"The notion that a simple drug acting on the serotonin system, buspirone, proved useful in short, four-hour testing performed in two patients is fascinating," Okun said. "Caution, however, should be exercised in interpreting these results. No conclusion can be drawn concerning long-term treatment efficacy, and these results cannot be applied in patients who did not receive fetal cell transplants."

The most common treatment for Parkinson's is levodopa, which is converted into dopamine in the brain. Over time, people who take levodopa can also develop dyskinesias, but perhaps because of a different mechanism, Politis said.

Previous research has hinted at the role of serotonin in dyskinesias for other Parkinson's patients.

More information

The National Parkinson Foundation has more on the disease.

SOURCES: Marios Politis, Ph.D., M.D, clinical science, Imperial College London; Michael S. Okun, M.D., national medical director, National Parkinson Foundation; June 30, 2010, Science Translational Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Higher cancer rates found in liver transplant patients receiving cyclosporine for immunosuppression
2. Israel Penn Registry marks 3,000 consults for transplant care providers
3. The experience of arterial reconstruction in adult-to-adult living donor liver transplantation
4. Longer Antiviral Therapy Reduces Lung Transplant Complications
5. Immune system helps transplanted stem cells navigate in central nervous system
6. Lack of private insurance contribute to higher deaths among black heart transplant patients
7. Color-coded tracking method helps scientists analyze outcomes of newly transplanted tissue
8. Shortage of Transplant Organs Spurs Proposals But No Solution
9. Gene pattern may identify kidney transplant recipients who dont need lifelong anti-rejection drugs
10. Gene pattern may identify kidney transplant recipients who dont need life-long anti-rejection drugs
11. African-Americans and women are less likely to undergo bone marrow transplantation
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Parkinson's Transplant Mystery Solved, Researchers Say 
(Date:6/24/2016)... York, NY (PRWEB) , ... June 24, 2016 ... ... publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as a ... that “the most beautiful women in the world, and the most handsome men, ...
(Date:6/24/2016)... ... , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event ... that have been wounded in battle and their families. Venture Construction Group is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... To succeed ... Most providers, however, are unsure how to move forward, given the need to ... a path forward tailored to an organization’s specific needs. , PYA Principal Martie ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Seema Daulat, a native Texan and ... South Lamar location as of July 13, 2016. , Dr. Daulat earned her Doctorate ... student, she regularly volunteered at the Agape Clinic serving Dallas’ underprivileged community. , Following ...
(Date:6/23/2016)... ... June 23, 2016 , ... The Mechille Wilson Agency, a Texas-based insurance ... and the surrounding region, is initiating a charity drive to assist a student to ... for a scholarship fund that will be presented to the chosen student to help ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
Breaking Medicine Technology: